The first long-acting injectable PrEP, an option to prevent HIV infection among those at-risk for the disease, was approved by the Food and Drug Administration, the agency announced this week. Apretude, from GlaxoSmithKline, will be available for anyone considered at-risk for HIV and weighs at least 77 pounds. The injection is administered as two shots … Continue reading Injectable PrEP to combat HIV approved by FDA